Advertisement
Advertisement
VKTX
Viking Therapeutics, Inc
31.57
USDSponsored
+0.25
+0.79%
May 13, 15:22 UTC -4
Open
VKTX Earnings Reports
Positive Surprise Ratio
VKTX beat 22 of 42 last estimates.
52%
Next Report
Date of Next Report
Jul 21, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$1.15
Implied change from Q1 26 (Revenue/ EPS)
--
/-16.06%
Implied change from Q2 25 (Revenue/ EPS)
--
/+101.75%
Viking Therapeutics, Inc earnings per share and revenue
On Apr 29, 2026, VKTX reported earnings of -1.37 USD per share (EPS) for Q1 26, missing the estimate of -1.03 USD, resulting in a -32.46% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.48% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of -1.15 USD, with revenue projected to reach -- USD, implying an decrease of -16.06% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Vor Biopharma Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.73
Surprise
+7.38%
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.01
Actual
$0.22
Surprise
+2278.22%
Immunic, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.93
Actual
-$1.08
Surprise
-16.03%
Humacyte, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.11
Actual
-$0.09
Surprise
+24.05%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
PDS Biotechnology Corporation Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.13
Surprise
+15.03%
FAQ
What were Viking Therapeutics, Inc's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Viking Therapeutics, Inc reported EPS of -$1.37, missing estimates by -32.46%, and revenue of $0.00, 0% as expectations.
How did the market react to Viking Therapeutics, Inc's Q1 2026 earnings?
The stock price moved down -0.48%, changed from $31.33 before the earnings release to $31.18 the day after.
When is Viking Therapeutics, Inc expected to report next?
The next earning report is scheduled for Jul 21, 2026.
What are the forecasts for Viking Therapeutics, Inc's next earnings report?
Based on 10
analysts, Viking Therapeutics, Inc is expected to report EPS of -$1.15 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement